A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

September 26, 2025

Primary Completion Date

November 6, 2026

Study Completion Date

November 6, 2026

Conditions

Psoriasis

Interventions

DRUG

HSK44459 dose level 1

HSK44459 dose level 1 oral administration

DRUG

HSK44459 dose level 2

HSK44459 dose level 2 orally administration

DRUG

placebo

placebo oral adminisitration

Trial Locations (1)

Hangzhou First People's Hospital, Hangzhou

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT07150988 - A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter